Aptinyx Inc. Company Review & Valuation

APTX
Nasdaq
Latest Price
2.20USD
Market Capitalization
148.97mUSD

About Aptinyx Inc.

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders.

It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

The company has a collaboration agreement with Allergan plc.

Aptinyx Inc.

was founded in 2015 and is headquartered in Evanston, Illinois.

Industry
Biotechnology
HQ Location
Evanston, Illinois

Stock Price

Price data not available for Aptinyx Inc..

Performance

Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

↑back to top

Valuu.io

Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2021 Valuu Analytics Sàrl